Bone marrow MxA staining reflects anifrolumab response in formerly treatment-refractory systemic lupus erythematosus with initial pancytopenia

Aringer M Costenbader K Daikh D , et al. 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019; 71: 1400–1412.

Holzinger D Jorns C Stertz S , et al. Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. J Virol 2007; 81: 7776–7785.

Ronni T Melén K Malygin A , et al. Control of IFN-inducible MxA gene expression in human cells. J Immunol 1993; 150: 1715–1726.

Lodi L Mastrolia MV Bello F , et al. Type I interferon–related kidney disorders. Kidney Int 2022; 101: 1142–1159.

Gao S von der Malsburg A Dick A , et al. Structure of myxovirus resistance protein a reveals intra-and intermolecular domain interactions required for the antiviral function. Immunity 2011; 35: 514–525.

Crow MK . Advances in understanding the role of type I interferons in systemic lupus erythematosus. Curr Opin Rheumatol 2014; 26: 467–474.

Peng L Oganesyan V Wu H , et al. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody. Oxfordshire: Taylor & Francis, 2015, pp. 428–439.